A detailed history of Kynam Capital Management, LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Kynam Capital Management, LP holds 5,722,057 shares of SNDX stock, worth $109 Million. This represents 9.15% of its overall portfolio holdings.

Number of Shares
5,722,057
Previous 5,660,000 1.1%
Holding current value
$109 Million
Previous $135 Million 12.79%
% of portfolio
9.15%
Previous 14.14%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$18.82 - $23.79 $1.17 Million - $1.48 Million
62,057 Added 1.1%
5,722,057 $117 Million
Q4 2023

Feb 14, 2024

BUY
$11.39 - $21.67 $23.5 Million - $44.6 Million
2,060,000 Added 57.22%
5,660,000 $122 Million
Q3 2023

Nov 14, 2023

BUY
$14.52 - $21.77 $4.91 Million - $7.36 Million
337,996 Added 10.36%
3,600,000 $52.3 Million
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $1.08 Million - $1.25 Million
56,018 Added 1.75%
3,262,004 $68.3 Million
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $13.3 Million - $18.7 Million
644,799 Added 25.18%
3,205,986 $67.7 Million
Q4 2022

Feb 14, 2023

BUY
$20.64 - $26.24 $5.95 Million - $7.56 Million
288,272 Added 12.68%
2,561,187 $65.2 Million
Q3 2022

Nov 14, 2022

SELL
$18.51 - $24.79 $4.43 Million - $5.93 Million
-239,325 Reduced 9.53%
2,272,915 $54.6 Million
Q2 2022

Aug 15, 2022

BUY
$13.64 - $19.48 $7.9 Million - $11.3 Million
579,440 Added 29.98%
2,512,240 $48.3 Million
Q1 2022

May 13, 2022

BUY
$14.84 - $22.15 $14.5 Million - $21.6 Million
976,635 Added 102.14%
1,932,800 $33.6 Million
Q4 2021

Feb 14, 2022

BUY
$15.23 - $22.47 $14.6 Million - $21.5 Million
956,165 New
956,165 $20.9 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.07B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Kynam Capital Management, LP Portfolio

Follow Kynam Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Kynam Capital Management, LP with notifications on news.